An updated systematic review and meta-analysis of the predictive value of serum biomarkers in the assessment of fever during neutropenia in children with cancer

Pediatric Infectious Disease Journal

Volumn 32, Issue 10, 2013, Pages

  Haeusler, Gabrielle M ^a,b   Carlesse, Fabianne ^c   Phillips, Robert S ^d,e  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d UNIVERSITY OF YORK   (United Kingdom)

^e LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Biomarker; Child; Febrile neutropenia; Review; Risk

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; GAMMA INTERFERON; GLUCOSE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; PROCALCITONIN; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADVERSE OUTCOME; BACTERIAL INFECTION; CHILDHOOD CANCER; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; FEBRILE NEUTROPENIA; HOSPITAL ADMISSION; HUMAN; INFECTION; INTENSIVE CARE; META ANALYSIS; OUTCOME ASSESSMENT; PNEUMONIA; PREDICTIVE VALUE; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; REVIEW; SENSITIVITY AND SPECIFICITY; SEPSIS; SYSTEMATIC REVIEW;

ADOLESCENT; C-REACTIVE PROTEIN; CALCITONIN; CHILD; CHILD, PRESCHOOL; FEBRILE NEUTROPENIA; HUMANS; INFANT; INTERLEUKIN-8; NEOPLASMS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84891831404     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31829ae38d     Document Type: Review

References (48)

1. Hann I, Viscoli C, Paesmans M, et al. A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORT C studies. Brit J Haem. 1997;99: 580-588.
2. Teuffel O, Sung L. Advances in management of low-risk febrile neutropenia. Curr Opin Pediatr. 2012;24: 40-45.
3. Phillips RS, Sutton AJ, Riley RD, et al.; PICNICC Collaboration. Predicting infectious complications in neutropenic children and young people with cancer (IPD protocol). Syst Rev. 2012;1: 8.
4. Phillips RS, Wade R, Lehrnbecher T, et al. Systematic review and metaanalysis of the value of initial biomarkers in predicting adverse outcome in febrile neutropenic episodes in children and young people with cancer. BMC Med. 2012;10: 6.
5. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69: 89-95.
6. Lijmer JG, Bossuy PM. Diagnostic testing and prognosis: the randomised controlled trial in diagnostic research. In: Knottnerus J, ed. The Evidence Base of Clinical Diagnosis: How to Do Diagnostic Research. London: Wiley-Blackwell; 2002.
7. Tacconelli E. Systematic Review: CRD's Guidance for Undertaking Reviews in Health Care. 3rd ed. York, UK: University of York, Centre for Reviews and Dissemination; 2009.
8. Phillips B, Stewart LA, Sutton AJ. 'Cross-hairs' plots for diagnostic metaanalysis. Res Synth Methods. 2011;1: 308-315.
9. Ammann RA, Bodmer N, Hirt A, et al. Predicting adverse events in children with fever and chemotherapy-induced neutropenia: the prospective multicenter SPOG 2003 FN study. J Clin Oncol. 2010;28: 2008-2014.
10. Asturias EJ, Corral JE, Quezada J. Evaluation of six risk factors for the development of bacteremia in children with cancer and febrile neutropenia. Curr Oncol. 2010;17: 59-63.
11. Avabratha KS, Rau AT, Venkataravanamma P, et al. Significance of C-reactive protein during febrile neutropenia in pediatric malignancies. Indian Pediatr. 2009;46: 797-799.
12. Cost C, Leonard D, Leavey P. Utilizing cytokines to predict bacteremia in 120 pediatric patients with febrile neutropenia. In: 24th Annual Meeting of the American Society of Pediatric Hematology Oncology, ASPHO 2011. Baltimore, MD: Pediatric Blood Cancer; 2011: 922.
13. Hatzistilianou M, Rekliti A, Athanassiadou F, et al. Procalcitonin as an early marker of bacterial infection in neutropenic febrile children with acute lymphoblastic leukemia. Inflamm Res. 2010;59: 339-347.
14. Hodge G, Scott J, Osborn M, et al. Increased T regulatory cells and decreased Th1 pro-inflammatory cytokines correlate with culture-positive infection in febrile neutropenia childhood oncology patients. Cytokine. 2011;53: 286-288.
15. Kharya G, Dinand V, Prakash A, et al. Interleukin 6 and procalcitonin are good early markers of sepsis in children with febrile neutropenia. In: International Society of Paediatric Oncology, SIOP XXXXII Congress. Boston, MA: Wiley-Liss Inc; 2010: 953.
16. Lodahl D, Schrøder H. Procalcitonin adds to diagnosis, but does not reduce initial antibiotics in febrile neutropenic children. Dan Med Bull. 2011;58:A4233.
17. Mian A, Bhutta A, Prodhan P, et al. Increased expression of inflammatory proteins predicts intensive care unit admission among children with fever and neutropenia. Crit Care Med. 2009;37:A1-A567.
18. Miedema KG, de Bont ES, Elferink RF, et al. The diagnostic value of CRP, IL-8, PCT, and sTREM-1 in the detection of bacterial infections in pediatric oncology patients with febrile neutropenia. Support Care Cancer. 2011;19: 1593-1600.
19. Nishikawa T, Okamoto Y, Kodama Y, et al. Serum derivative of reactive oxygen metabolites (d-ROMs) in pediatric hemato-oncological patients with neutropenic fever. Pediatr Blood Cancer. 2010;55: 91-94.
20. Reitman A, Pisk R, Gates III J, et al. Serial procalcitonin levels for bacteremia in pediatric patients with fever and severe neutropenia. In: 23rd Annual Meeting of American Society of Pediatric Hematology Oncology (ASPHO). Montreal, Canada: Pediatric Blood Cancer; 2010.
21. Richardson MW, Grewal SS, Visintainer PF. Emesis predicts bacteremia in immunocompromised children with central venous catheters and fever. Cancer. 2009;115: 3335-3340.
22. Santolaya ME, Alvarez AM, Aviles CL, et al. Predictors of severe sepsis not clinically apparent during the first twenty-four hours of hospitalization in children with cancer, neutropenia, and fever: a prospective, multicenter trial. Pediatr Infect Dis J. 2008;27: 538-543.
23. Spasova MI, Terzieva DD, Tzvetkova TZ, et al. Interleukin-6, interleukin-8, interleukin-10, and C-reactive protein in febrile neutropenia in children with malignant diseases. Folia Med (Plovdiv). 2005;47: 46-52.
24. Secmeer G, Devrim I, Kara A, et al. Role of procalcitonin and CRP in differentiating a stable from a deteriorating clinical course in pediatric febrile neutropenia. J Pediatr Hematol Oncol. 2007;29: 107-111.
25. Katz JA, Mustafa MM, Bash RO, et al. Value of C-reactive protein determination in the initial diagnostic evaluation of the febrile, neutropenic child with cancer. Pediatr Infect Dis J. 1992;11: 708-712.
26. Riikonen P, Jalanko H, Hovi L, et al. Fever and neutropenia in children with cancer: diagnostic parameters at presentation. Acta Paediatr. 1993;82: 271-275.
27. El-Maghraby SM, Moneer MM, Ismail MM, et al. The diagnostic value of C-reactive protein, interleukin-8, and monocyte chemotactic protein in risk stratification of febrile neutropenic children with hematologic malignancies. J Pediatr Hematol Oncol. 2007;29: 131-136.
28. Ammann RA, Hirt A, Lüthy AR, et al. Identification of children presenting with fever in chemotherapy-induced neutropenia at low risk for severe bacterial infection. Med Pediatr Oncol. 2003;41: 436-443.
29. Santolaya ME, Cofre J, Beresi V. C-reactive protein: a valuable aid for the management of febrile children with cancer and neutropenia. Clin Infect Dis. 1994;18: 589-595.
30. Kitanovski L, Jazbec J, Hojker S, et al. Diagnostic accuracy of procalcitonin and interleukin-6 values for predicting bacteremia and clinical sepsis in febrile neutropenic children with cancer. Eur J Clin Microbiol Infect Dis. 2006;25: 413-415.
31. Hitoglou-Hatzi S, Hatzistilianou M, Gougoustamou D, et al. Serum adenosine deaminase and procalcitonin concentrations in neutropenic febrile children with acute lymphoblastic leukaemia. Clin Exp Med. 2005;5: 60-65.
32. Santolaya ME, Alvarez AM, Becker A, et al. Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia, and fever. J Clin Oncol. 2001;19: 3415-3421.
33. Hatzistilianou M, Rekleity A, Athanassiadou F, et al. Serial procalcitonin responses in infection of children with secondary immunodeficiency. Clin Invest Med. 2007;30:E75-E85.
34. Riikonen P, Saarinen UM, Teppo AM, et al. Cytokine and acute-phase reactant levels in serum of children with cancer admitted for fever and neutropenia. J Infect Dis. 1992;166: 432-436.
35. Lehrnbecher T, Fleischhack G, Hanisch M, et al. Circulating levels and promoter polymorphisms of interleukins-6 and 8 in pediatric cancer patients with fever and neutropenia. Haematologica. 2004;89: 234-236.
36. Diepold M, Noellke P, Duffner U, et al. Performance of Interleukin-6 and Interleukin-8 serum levels in pediatric oncology patients with neutropenia and fever for the assessment of low-risk. BMC Infect Dis. 2008;8: 28.
37. Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel. J Infect Dis. 1990;161: 397-401.
38. Adams-Chapman I, Stoll B. Systemic inflammatory response syndrome. Semin Pediatr Infect Dis. 2001;12: 5-16.
39. Goldstein B, Giroir B, Randolph A; International Consensus Conference on Pediatric Sepsis. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med. 2005;6: 2-8.
40. Ek T, Pinkava M, Abrahamsson J. Ara-C fever and infections after highdose ara-C treatment in pediatric lymphoid malignancies. J Pediatr Hematol Oncol. 2005;27: 364-369.
41. Standage SW, Wong HR. Biomarkers for pediatric sepsis and septic shock. Expert Rev Anti Infect Ther. 2011;9: 71-79.
42. Irwin AD, Carrol ED. Procalcitonin. Arch Dis Child Educ Pract Ed. 2011;96: 228-233.
43. Maruna P, Nedelníková K, Gürlich R. Physiology and genetics of procalcitonin. Physiol Res. 2000;49(suppl 1):S57-S61.
44. McWilliam S, Riordan A. How to use: C-reactive protein. Arch Dis Child Educ Pract Ed. 2010;95: 55-58.
45. Delebarre M, Dubos F, Macher E, et al. Identifying high-risk patients for severe infection in children with chemotherapyinduced febrile neutropenia: A new decision rule (abstract). Pediatr Blood Cancer. 2010;55: 823.
46. Lin SG, Hou TY, Huang DH, et al. Role of procalcitonin in the diagnosis of severe infection in pediatric patients with fever and Neutropenia-a systemic review and meta-analysis. Pediatr Infect Dis J. 2012;31:e182-e188.
47. Phillips B, Wade R, Stewart LA, et al. Systematic review and meta-analysis of the discriminatory performance of risk prediction rules in febrile neutropaenic episodes in children and young people. Eur J Cancer. 2010;46: 2950-2964.
48. Phillips RS, Lehrnbecher T, Alexander S, et al. Updated systematic review and meta-analysis of the performance of risk prediction rules in children and young people with febrile neutropenia. PLoS One. 2012;7:e38300.